Actively Recruiting

Phase Not Applicable
Age: 18Years - 65Years
All Genders
ID06569550

Neuromodulation of the Left Premotor Cortex With Transcranial Magnetic Stimulation to Alleviate Fatigue in Multiple Sclerosis - a Randomised Controlled Clinical Trial

Led by Danish Research Centre for Magnetic Resonance · Updated on 2026-01-28

60

Participants Needed

1

Research Sites

8 weeks

Total Duration

On this page

Sponsors

D

Danish Research Centre for Magnetic Resonance

Lead Sponsor

D

Danish Multiple Sclerosis Center

Collaborating Sponsor

AI-Summary

What this Trial Is About

Researchers are investigating whether repetitive Transcranial Magnetic Stimulation (rTMS) applied to the left premotor cortex can reduce fatigue in patients with Multiple Sclerosis (MS) and if this approach is feasible as a treatment. The study also aims to better understand fatigue in MS by comparing real rTMS with sham (inactive) rTMS. The primary focus is to see if rTMS decreases fatigue symptoms and changes brain activity balance in the targeted area. Participants will receive either real or sham rTMS for 30 minutes daily over five consecutive days, Monday through Friday. The treatment uses a specialized coil guided by MRI and robotic positioning to target the left dorsal premotor cortex. The study involves a baseline period, the intervention phase, and a follow-up period. Brain scans using ultra-high field MRI and neurophysiological tests are conducted at baseline, during, and after treatment to measure changes. During the study, participants will visit the clinic before treatment and six days after to undergo clinical testing, MRI scans, and neurophysiological measurements. They will keep a fatigue diary and wear an activity tracker before, during, and after intervention. Additional online questionnaires are completed one day and four weeks after treatment. The main outcome measured is the change in fatigue severity from baseline to six days after intervention, supported by brain imaging and other fatigue-related assessments. Safety and compliance are closely monitored throughout the trial.

CONDITIONS

Brief Title

Fatigue Alleviation Through Neuromodulating Therapy in Multiple Sclerosis

Who Can Participate

Age: 18Years - 65Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adults aged 18 to 65 years
  • Confirmed diagnosis of relapsing-remitting or secondary progressive multiple sclerosis according to recent McDonald's criteria, diagnosed more than 3 months ago
  • Experiencing fatigue with a Fatigue Scale for Motor and Cognitive Symptoms (FSMC) score indicating at least moderate fatigue (>53)
  • Stable multiple sclerosis medication for at least 3 months
Not Eligible

You will not qualify if you...

  • Pregnancy or potential to become pregnant without effective contraception
  • Multiple sclerosis relapse or steroid treatment within the past 3 months
  • Current or recent (within 3 months) treatment specifically targeting fatigue
  • History of neurological diseases other than multiple sclerosis or other significant medical conditions
  • Expanded Disability Status Scale (EDSS) score greater than 6.5
  • Major psychiatric disorders, including current clinical depression
  • Use of medications primarily affecting the central nervous system or neurotransmission, except SSRIs or SNRIs
  • Presence of pacemaker or other implanted electronic devices
  • Any intracranial metal implants
  • Metallic implants incompatible with MRI scanning
  • Claustrophobia
  • Patient or close relatives with epilepsy
  • Current drug or alcohol abuse

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Baseline Assessment

Duration - 1 day

Participants undergo clinical testing, MRI scans, and wear a wrist accelerometer while filling out a fatigue diary to establish baseline measurements.

1 baseline visit (in-person)

Treatment

Duration - 5 sequential days

Participants receive 5 daily sessions of repetitive transcranial magnetic stimulation (rTMS) targeting the left premotor cortex to alleviate fatigue symptoms.

5 daily visits (in-person)

Immediate Post-Treatment Assessment

Duration - 1 day

Participants undergo follow-up MRI scans and neurophysiological testing immediately after the last treatment session, while continuing to wear a wrist accelerometer and fill out a fatigue diary.

1 visit (in-person)

Follow-up

Duration - 6 days after last treatment to 28 days post treatment

Participants return for clinical testing, MRI scans, and complete electronic questionnaires to assess fatigue and fatiguability after treatment.

3 visits: at 6 days post treatment, 1 day post treatment, and 28 days post treatment (some visits may be electronic questionnaires)

Trial Site Locations

Total: 1 location

1

Danish Research Centre for Magnetic Resonance

Hvidovre, Capital Region, Denmark, 2650

Actively Recruiting

Loading map...

Research Team

H

Hartwig R Siebner, MD, DMSc

S

Sofus AD Nygaard, MD

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Similar Trials

Functional Assessment of Balance and Gait and Correlation Wi...

Multiple Sclerosis

Actively Recruiting

2 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Published Research Related To This Trial

Repetitive transcranial magnetic stimulation to alleviate fatigue in multiple sclerosis-study protocol for a randomized sham-controlled double-blinded clinical trial.

Sofus Nygaard, Mads Alexander Just Madsen, Vanessa Wiggermann...

https://pubmed.ncbi.nlm.nih.gov/41835064